April 25th 2024
Despite a wealth of knowledge, pharmacists are frequently not consulted as part of the decision-making team in atrial fibrillation management.
Continuing the Conversation: Considerations for Pharmacists to Individualize DOAC Therapy
May 29, 2024 | 1:00 PM ET
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Recent Advances in Omega-3 Fatty Acids to Reduce Risk of ASCVD in Patients With Elevated Triglyceride Levels
0.75 Credit / Cardiology
View More
Introduction to Anticoagulation and the Appropriate Patient
1.0 Credit / Cardiology
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
The Treatment Landscape and a Review of Approved DOAC Agents
1.0 Credit / Cardiology
View More
Maximizing Patient Outcomes Through Pharmacist-Led Homozygous Familial Hypercholesterolemia Management
1.0 Credit / Cardiology
View More
Setting the Stage: An Introduction to Worsening Heart Failure Events in Patients With Heart Failure With Reduced Ejection Fraction
1.0 Credit / Cardiology
View More
Navigating the Therapeutic Landscape of Homozygous Familial Hypercholesterolemia
1.0 Credit / Cardiology
View More
Understanding the Challenges of Homozygous Familial Hypercholesterolemia
1.0 Credit / Cardiology
View More
The Role of the Pharmacist in Optimizing DOAC Utilization Across Practice Settings
1.0 Credit / Cardiology
View More
Soluble Guanylate Cyclase Stimulators in the Management of Worsening Heart Failure With Reduced Ejection Fraction
1.0 Credit / Cardiology
View More
Individualizing Care for Patients With Heart Failure: The Role of the Pharmacist in Optimizing Education and Improving Adherence
1.0 Credit / Cardiology
View More
Advancing Chronic Worsening Heart Failure Treatment: The Critical Role of Pharmacists in Therapy Integration
1.0 Credit / Cardiology
View More
Iron Deficiency and Anemia in Heart Failure: Clinical Applications for the Use of Intravenous Iron
1.5 Credits / Cardiology
View More
Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction
1.0 Credits / Cardiology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
AHA: Type 2 diabetes mellitus a risk factor for heart failure
June 14th 2019Type 2 diabetes mellitus is a risk factor for incident heart failure, according to a new scientific statement from the American Heart Association (AHA), and it increases the risk of morbidity and mortality in patients with established disease.